Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAP-001 in Gout Patients With Hyperuricemia

NCT03857165 is registered in ClinicalTrials.gov with Shanton Pharma Co., Ltd. as lead sponsor.

NCT NCT03857165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03857165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAP-001 in Gout Patients With Hyperuricemia
Lead sponsor
Shanton Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 24, 2018
Completion date
October 31, 2019
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gout, hyperuricemia